Free shipping on all orders over $ 500

 About 30 results found for searched term "G-1" (0.001 seconds)

Cat.No.  Name Target
M1644 AG-014699 phosphate PARP
PF-01367338, Rucaparib phosphate
AG-014699 (PF-01367338, Rucaparib) is a PARP inhibitor with a Ki of 1.4 nM.
M1645 AG14361 PARP
AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM.
M1658 Axitinib VEGFR/PDGFR
AG-013736
Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit.
M1686 Bortezomib (PS-341) Proteasome
Velcade; PS-341; LDP 341; MG 341; NSC 681239
Bortezomib (PS-341) is a highly selective proteasome inhibitor with a ki value of 6nM.
M1713 GDC-0449 (Vismodegib) Smo
Vismodegib, HhAntag691
GDC-0449 (Vismodegib) is a potent and specific hedgehog pathway inhibitor with IC50 values of 1.4 and 3.0μM for inhibition of ABCG2 and Pgp respectively.
M1715 GDC-0941 (Pictilisib) PI3K
Pictilisib
GDC-0941 is a selective and potent inhibitor of Class I PI3K, p110a IC50=0.003uM, U87MG IC50=0.95μM.
M1716 Gemcitabine Hydrochloride DNA/RNA Synthesis
Gemzar, LY-188011
Gemcitabine (Gemzar, LY188011) inhibits DNA synthesis with an IC50 of 0.06 µM.
M1717 GSK1904529A IGF-1R
GSK1904529A selectively inhibits IGF-IR and IR with IC50s of 27 and 25 nmol/L, respectively.
M1719 GSK461364 PLK
GSK461364A
GSK461364 is a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1) with a Ki of 2.2 nM.
M1721 AZD4547 FGFR
Fexagratinib; ABSK091
AZD4547 is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively.
M1733 TG101348 JAK
Fedratinib; SAR302503
TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM.
M1758 Foretinib c-Met
XL880, GSK1363089
Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET.
M1759 GSK1120212 (Trametinib) MEK
JTP-74057, GSK212
Trametinib (GSK1120212; Jtp-74057) is an orally effective MEK inhibitor with IC50 of 2 nM against MEK1 and MEK2, respectively. Trametinib can activate autophagy and induce apoptosis.
M1761 Vemurafenib (PLX4032) Raf
RG7204; RO5185426
Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy.
M1779 SGI-1776 Pim
SGI-1776 is novel small molecule inhibitor of PIM kinase activity with IC50 of 7 ± 1.8, 363 ± 27.6 and 69 ± 9.2 nM for Pim-1, Pim-2, and Pim-3, respectively.
M1790 MGCD0103 HDAC
Mocetinostat
MGCD0103 is a novel HDAC inhibitor, highly specific for classes I and IV HDACs, with IC50 of 0.15, 0.29 and 1.66 μM for HDAC 1, HDAC 2 and HDAC 3 respectively.
M1795 TGX-221 PI3K
TGX-221 is a potent and specific cell permeable inhibitor of Phosphatidylinositol 3-kinase (PI3K) p110β(IC50 = 10nM).
M1797 Retigabine Potassium Channel
Ezogabine; D2312; D-23129
Retigabine is a KCNQ/Kv7 potassium channel activator which functions by enhancing potassium currents via stabilizing the open conformation of the Kv7.2-7.3 channels.
M1799 Imatinib Mesylate Src-bcr-Abl
Gleevec, Glivec, CGP-57148B, STI-571
Imatinib Mesylate is a Bcr-Abl tyrosine kinase inhibitor, with IC50 values of 2.9 and 3.9 μM for the inhibition of T-cell proliferation stimulated by PHA and DCs respectively.
M1855 Dabrafenib Mesylate Raf
GSK-2118436B
Dabrafenib (GSK2118436) is a selective, orally bioavailable inhibitor of Mutant B-raf (BRAF) protein kinase with potential antineoplastic activity.
M1867 PAC-1 Caspase
Procaspase activating compound 1
PAC-1 is a procaspase-activating compound; activates procaspase-3 to produce caspase-3 (EC50 = 0.22 μM).
M1886 TG100-115 PI3K
TG100-115 is a selective PI3K γ/δ inhibitor with IC50 values of 83 and 235 nM respectively.
M1887 TG101209 JAK
TG101209 is a novel small molecule, ATP-competitive JAK2-selective kinase inhibitor (IC50 = 6 nM).
M1902 MG132 Proteasome
Z-Leu-Leu-Leu-al; MG-132
MG132 is a specific and potent cell-permeable proteasome inhibitor (IC50 = 100 nM, Ki = 4 nM).
M1909 GW 791343 dihydrochloride P2 Receptor
GW 791343 dihydrochloride is a non-competitive inhibitor of human P2X(7) receptor.
M1931 GSK2126458 PI3K
Omipalisib
GSK2126458 is a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) with low picomolar to subnanomolar activity.
M1932 GSK1838705A ALK
GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, respectively.
M1945 CAL-101 (Idelalisib) PI3K
Idelalisib; GS-1101
CAL-101 (Idelalisib; GS-1101) is an oral PI3Kδ-specific inhibitor that has shown preclinical and clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
M1978 GSK1059615 PI3K
GSK1059615 is a potent, ATP-competitive inhibitor of PI 3-kinase alpha (PI3Kα) with IC50 of 2 nM.
M1979 Elvitegravir Integrase
GS-9137, EVG
Elvitegravir (EVG) is a HIV integrase inhibitor with IC50 of 0.7 nM, 2.8 nM and 1.4 nM for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD, respectively.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.